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Background: The health benefits of omega-3 fatty acids from fish are well known, and fish oil supplements are
used widely in a preventive manner to compensate the low intake in the general population. The aim of this open-
label study was to determine if consumption of a high potency fish oil supplement could improve blood levels of
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and impact SF-12 mental and physical health scores
in healthy adults.
Methods: A novel virtual clinical research organization was used along with the HS-Omega-3 Index, a measure of
EPA and DHA in red blood cell membranes expressed as a percentage of total fatty acids that has been shown to
correlate with a reduction in cardiovascular and other risk factors. Briefly, adult subjects (mean age 44 years) were
recruited from among U.S. health food store employees and supplemented with 1.1 g/d of omega-3 from fish oil
(756 mg EPA, 228 mg DHA, Minami Nutrition® MorEPA® Platinum) for 120 days (n = 157).
Results: Omega-3 status and mental health scores increased with supplementation (p < 0.001), while physical
health scores remained unchanged.
Conclusions: The use of a virtual, web-based platform shows considerable potential for engaging in clinical
research with normal, healthy subjects. A high potency fish oil supplement may further improve omega-3 status in
a healthy population regularly consuming an omega-3 supplement.
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Considerable evidence has demonstrated that increasing
consumption of omega-3 fatty acids can benefit health,
most notably by reducing cardiovascular disease and its
associated risk factors [1-5]. Over the past several decades,
evidence has emerged indicating that higher intakes of
omega-3 are associated with a significant reduction in all-
cause mortality [6,7], and a 2006 meta-analysis of ran-
domized controlled trials found that fish oil significantly
reduced total mortality [8]. Specifically, eicosapentaenoic* Correspondence: br@atrium-innovations.com
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reproduction in any medium, provided the oracid (EPA) and docosahexaenoic acid (DHA) have been
identified as health promoting. Both EPA and DHA may
improve cardiovascular health by several mechanisms. In
general, both EPA and DHA compete with arachidonic
acid (omega-6) in cyclooxygenase and lipoxygenase
synthesis, resulting in net anti-inflammatory effects.
Both reduce blood viscosity without a significant effect
on platelet or clotting factors, and both have positive
effects on blood lipids, most consistently a reduction in
triglyceride concentrations [9]. However, some recent
analyses have suggested that protection against cardio-
vascular outcomes may not be as pronounced as indicated
by earlier investigations [10,11], raising awareness that
additional controlled studies are needed.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Udani and Ritz Nutrition Journal 2013, 12:112 Page 2 of 5
http://www.nutritionj.com/content/12/1/112Data are also emerging connecting omega-3 fish oils
with cognitive function and mental health status [12-16].
Population studies and preliminary clinical data demon-
strate that omega-3 fatty acids may help elevate mood in
depressed subjects [13,14]. In particular, high-EPA inter-
ventions and higher plasma EPA may be associated with
improved clinical outcomes [17], although more research
is needed in the application of EPA and fish oil in cogni-
tive and mental health.
Despite the clear need for more controlled studies in
specific populations and targeting specific clinical out-
comes, increasing blood EPA and DHA levels appears to
have a generally positive impact on health, and aware-
ness among the general population is high [18]. Because
of this, the use of fish oil supplements has increased
dramatically over the past decade, reaching sales of
$1.145 billion in 2011 and continuing to grow [19]. The
American Heart Association recommends an intake of
1 g/d of combined EPA and DHA from food or supple-
ments for secondary prevention [20], and concentrated
formulations of EPA and DHA are now available as both
dietary supplements and medications.
The aims of the present study were to investigate the
utilization of a new web-based program known as a vir-
tual clinical research organization (CRO) and to assess
the effects of a high potency fish oil on omega-3 status,
as well as mental and physical health scores, in healthy
adults who regularly consume an omega-3 supplement.
To our knowledge, this represents the first such use of a
virtual CRO to assess the impact of a nutritional inter-
vention on a quantifiable biomarker of health in the
general population.
Materials and methods
Virtual contract research organization (CRO)
The proprietary, web-based CRO program was deve-
loped by Medicus Research (Northridge, CA). This system
enabled researchers to enroll subjects through inclu-
sionary and exclusionary dialogue and track and monitor
progress by using survey tools and automatic prompts.
Researchers virtually followed up with subjects re-
garding completion of milestone events, adverse event
reporting, non-compliance issues, and other study
requirements.
Subject recruitment and protocol
The protocol was approved by Western IRB (Olympia,
WA) prior to the initiation of any study related activities.
Healthy subjects between the ages of 18 and 70 years
working at health food stores nationwide were recruited.
Subjects (n = 316) were invited via email to participate in
the study. Those who accepted the offer were directed to
a secure website where they took part in an onlineinformed consent procedure with electronic signature.
Participants then completed questions related to standard
inclusion and exclusion criteria such as age (18–70 years),
agreement to participate, and exclusion based on a
history of bleeding disorders, current use of anti-
coagulant medications, immune disorders, diabetes,
planned surgery, or pregnancy, among other criteria.
The subjects agreed to not change their current diet or
exercise program and to stop using all other dietary
supplements, including their present omega 3 fish oil
supplement, for a two-week wash-out period before
onset of the study and for the duration of the interven-
tion. Subjects were then scheduled to undergo a phone
screen with a trained clinical staff member. This phone
screening also ensured the subjects understood their
rights and responsibilities related to the study prior to
their participation.
The study duration was 120 days and featured a total
of 5 virtual CRO visits (V1-5). The subjects answered a
series of online questionnaires regarding medical history,
including an assessment of current supplemental omega-3
intake and web-based SF-12 Health Survey (V1). Subjects
then received via mail the first month’s supply of the study
product and the Omega-3 Index test kit, which was to be
completed on the same day they began taking the study
product. The study product provided a total of 1,100 mg
omega-3 s with 756 mg EPA, 228 mg DHA, and 300 IU
vitamin D3 in a single soft gel capsule (Minami Nutrition®
MorEPA® Platinum, provided by Garden of Life, West
Palm Beach, FL).
The subjects continued to receive monthly study prod-
uct via mail, as well as an email reminder from the Virtual
CRO for the 30-day (V2), 60-day (V3), 90-day (V4), and
120-day (V5) assessments. The emails directed the sub-
jects to a secure link for completion of the compliance
assessment, medical review, SF-12 Health Survey, and
adverse event questionnaires. The subjects were also ins-
tructed to complete the Omega-3 Index test at V5.
Compliance was assessed through the study website
where subjects were instructed to enter the number of
pills remaining in the study product bottle at the end of
each month.
Omega-3 status
Omega-3 status was quantified using the HS-Omega-3
Index, a finger stick blood test that measures the
amount of EPA and DHA in red blood cell membranes
expressed as the percentage of total fatty acids in the
membrane. The test was employed according to manufac-
turer’s instructions and results were analyzed and reported
by the manufacturer (OmegaQuant, Sioux Falls, SD).
Briefly, subjects received test kit directly from the labora-
tory responsible for testing, which includes a large bag,
small bag, test request form, collection card, alcohol pad,








Total users1 66% 21% 19%
Frequency
of use2
1/d 51% 72% 36%
2/d 30% 3% 16%
3/d 5% 1% -
4/d 2% 1% -
5+/d 1% 1% -
1/wk 11% 21% 47%
Dosage2 < 500 mg 10% 25% 63%
500–1000 mg 57% 42% 26%
>1000 mg 33% 33% 11%
1Percentage (%) of total study population.
2Percentage (%) of omega-3 supplement users by column.
Figure 1 Omega-3 Index in healthy subjects at baseline and
following fish oil supplementation, *p < 0.001.
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return envelope. Subjects were instructed to fill out test
request form and collection card first and wash hands
thoroughly before sterilizing either ring or middle finger
with the alcohol pad. Subjects used lancet on sterilized fin-
ger and applied drop of blood directly onto collection card,
blood was allowed to dry on the card for 15–20 minutes,
and card was then folded in half over the spot and placed
in the small bag with desiccant. The small bag was
placed in the large bag along with the test request form,
and then the large bag was placed in return envelope.
Subjects were instructed to return the envelope via mail
on the same day as collection. The data management
team received the results.
SF-12 health survey
The subjective assessment of mental and physical health
as composite scores utilized a shortened, validated version
of the SF-36 health survey created by Quality Metric and
in use since 1994 [21-23]. The scoring system applied was
from Positive Aging Resource Center, and the reference
range of scores had a cutoff of 50 for Physical Compo-
nent Summary (PCS) and 42 for Mental Component
Summary (MCS).
Statistical analysis
All values are reported as the mean ± the standard error
of the mean (SEM) or as a percentage of total subjects,
and data were analyzed using SPSS (Chicago, IL). Paired
T-tests were used to test significance for the HS-Omega
3 Index (baseline versus day 120), and analysis of vari-
ance (1 by 4) was used to determine time effect of the
intervention on the SF-12 composite scores.
Results
A total of 316 subjects were recruited for the study, 251
subjects completed a baseline HS-Omega-3 Index assess-
ment, and 157 subjects completed all aspects of the trial
through 120 days. Non-completers were lost to follow-up.
Adverse events reported were not serious and were deter-
mined to not be associated with the study product. The
mean age of subjects was 44.3 ± 0.9 years. Table 1 provides
information on omega-3 supplement usage at baseline. No
other demographic data were obtained.
The HS-Omega-3 Index increased from 6.1% (range of
3.1-11.8%) at baseline to 7.3% (3.7-13.3%) at 120 days
(p < 0.001, Figure 1). This represents an approximate
20% increase over baseline. The baseline score of ap-
proximately 6% was higher than previously reported
baseline scores of approximately 4%, as expected,
reflecting regular use of omega-3 fatty acid supple-
ments [24,25]. The mental composite score increased
after 60 days and remained elevated through day 120(p < 0.001, Table 2). There was no change in the phy-
sical composite score at any time point during the
intervention.
Discussion
To our knowledge, the present study is the first to
report a significant increase in blood EPA and DHA
levels, as Omega-3 Index, in a group of healthy indi-
viduals who were regular consumers of fish oil sup-
plements at baseline. Maximizing the response to
omega-3 supplementation may be a prudent clinical
target for the reduction of certain risk factors, and
Omega-3 Index may be an appropriate biomarker for
assessing and monitoring the effectiveness of omega-3
supplementation.
An increase in the Omega-3 Index has been correlated
with reductions in cardiovascular risk factors, and low
Table 2 Mental and physical health composite scores in
healthy subjects at baseline and following fish oil
supplementation
Days
Baseline 60 90 120
Mental health 49.5 ± 0.5 52.5 ± 0.5* 53.0 ± 0.6* 53.5 ± 0.5*
Physical health 53.2 ± 0.3 53.1 ± 0.4 53.2 ± 0.4 53.86 ± 0.3
*p < 0.001 compared to baseline.
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sudden cardiac death [24-27]. Importantly, it has also
been suggested that an Omega-3 Index of greater than
8% was associated with a lower risk for acute coronary
syndromes and decreased morbidity and mortality in
those with cardiovascular disease [28]. Conversely, an
Omega-3 Index less than 4% was associated with a ten-
fold increase in risk of cardiac death compared to
subjects with an Omega-3 Index greater than 8% [29].
Inflammatory markers were also shown to be inversely
related to Omega-3 Index [30], and an Omega-3 Index
of 8% or higher was associated with slowed cellular
aging as measured by the five-year rate of telomere
shortening [31].
In the current study, we demonstrated a significant
increase in Omega-3 Index in 120 days of regular
supplementation with a high potency fish oil. Assuming
a clinical target of >8%, the percentage of subjects meeting
this target increased from 5.6% at baseline to 24.8% of
subjects following supplementation. Such an increase may
be expected to yield clinically relevant outcomes among
responders, although this would require further study. It
is unknown whether continued supplementation would
further raise Omega-3 Index scores beyond what was ob-
served at 120 days or increase the number of subjects
achieving a score of >8%, although this seems a reasonable
extrapolation of the current data.
The SF-12 health survey provides a quick assessment
of an individual’s physical and mental health. The aver-
age baseline mental health and physical health scores
from this study are similar to those previously reported
[32]. In this study, we also detected a small but signifi-
cant increase in mental health scores based on the SF-12
mental health composite compared to baseline. How-
ever, the study design did not include a placebo control,
and there are insufficient corroborative data to conclude
that omega-3 supplementation and a corresponding in-
crease in Omega-3 Index can improve cognitive function
in a healthy population.
The current study had certain limitations in design
and execution. First, information was not obtained about
the composition of omega-3 fatty acid products being
consumed prior to the study, and only a basic analysis ofomega-3 intake from food sources was performed (not
reported). Subjects were instructed to maintain normal
dietary habits, and fish consumption was not restricted.
Further, it is possible that the subjects could have self-
reported inaccurate information regarding their supple-
ment use; however, over-reporting of supplement use is
not likely as their omega-3 status was higher than what
has been reported in the typical population. Next, the
use of an open-label design creates the potential for bias
by both investigator and subject. The virtual CRO is
designed to track and monitor the subject compliance
with minimal human interaction and influence. While
this is a positive, the tradeoff may be in overall compli-
ance. While the absence of a placebo does not allow for
the determination of normal changes in blood EPA and
DHA levels associated with daily nutritional practices,
because the subjects had already been taking a fish oil
supplement, the baseline value served as the surrogate
placebo or comparator value. Further, it was impractical
and perhaps unethical, given the known health benefits
of omega-3 consumption, to restrict omega-3 supple-
mentation in a currently supplementing healthy popula-
tion for a prolonged period of 4 months. Therefore, it
was determined that a placebo was not required. Clearly,
the lack of a placebo arm does not allow for the assess-
ment of causality in the subjective assessment of mental
health scores.Conclusion
Overall, the combination of the virtual CRO method, the
use of the SF-12, and the self-administered Omega-3
Index finger prick blood test provided an appropriate,
effective, and efficient design for assessing the potential
impact of a nutritional supplement on biomarkers of
health in a non-diseased population. The current study
demonstrated significant improvements in blood EPA
and DHA status, and a small but significant increase in
subjective mental health scores, following the compliant
use of a high potency fish oil supplement in a healthy
population that had been previously taking a fish oil sup-
plement. Further studies are needed with more rigorous
design, extended duration, and the evaluation of clinical
endpoints to assess the relevance of high potency fish oil
supplementation in the general population. Additional
studies should evaluate the effectiveness of the virtual
CRO as a research tool in evaluating nutritional inter-
ventions in a healthy population, as such studies are
grossly lacking.Competing interests
The study was sponsored by Garden of Life, West Palm Beach, FL, a
subsidiary of Atrium Innovations, Inc. Medicus Research conducted the study
independent from the sponsor, such that the sponsor had no influence on
the outcome of the study.
Udani and Ritz Nutrition Journal 2013, 12:112 Page 5 of 5
http://www.nutritionj.com/content/12/1/112Authors’ contributions
Both authors conceived of the design. JKU oversaw the execution of the
study and data analysis including statistical analysis. Both authors read and
approved the final manuscript.
Acknowledgments
The authors recognize Karolyn Gazella and Kelly Gibson for their assistance in
preparing the manuscript.
Author details
1Medicus Research, 28720 Roadside Drive, Suite 310, Agoura, CA 91301, USA.
2Atrium Innovations Inc, 4 Hillman Drive, Suite 190, Chadds Ford, PA 19348,
USA. 3Nutrition Sciences Department, College of Nursing and Health
Professions, Drexel University, 245 N. 15th Street, Philadelphia, PA 19102,
USA.
Received: 23 April 2013 Accepted: 1 August 2013
Published: 8 August 2013
References
1. Harris WS, Mozaffarian D, Lefevre M, Toner CD, Colombo J, Cunnane SC,
Holden JM, Klurfeld DM, Morris MC, Whelan J: Toward establishing dietary
reference intakes for eicosapentaenoic and docosahexaenoic acids.
J Nutr 2009, 139(4):S804–S819.
2. Buckley JD, Howe PRC: Long-chain omega-3 polyunsaturated fatty acids
may be beneficial for reducing obesity – a review. Nutri 2010,
2:1212–1230.
3. Goldberg RB, Sabharwal AK: Fish oil in the treatment of dyslipidemia.
Curr Opin Endocrinol Diabetes Obes 2008, 15:167–174.
4. Cabo J, Alonso R, Mata P: Omega-3 fatty acids and blood pressure?
Br J Nutr 2012, 107(S2):195–200.
5. Djousse L, Biggs ML, Lemaitre RN, King IB, Song X, Ix JH, Mukamal KJ,
Siscovick DS, Mozaffarian D: Plasma omega-3 fatty acids and incident
diabetes in older adults. Am J Clin Nutr 2011, 94(2):527–533.
6. Nagata C, Takatsuka N, Shimizu H: Soy and fish oil intake and mortality in
a Japanese community. Am J Epidemiol 2002, 156:824–831.
7. Hu FB, Cho E, Roxrode KM, Albert CM, Manson JE: Fish and long-chain ω-3
fatty acid intake and risk of coronary heart disease and total mortality in
diabetic women. Circulation 2003, 107:1852–1857.
8. Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health:
evaluating the risks and the benefits. JAMA 2006, 296:1885–1899.
9. Calder PC: n-3 Fatty acids and cardiovascular disease: evidence explained
and mechanisms explored. Clin Sci 2004, 107:1–11.
10. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS: Association between
omega-3 fatty acid supplementation and risk of major cardiovascular
disease events: a systematic review and meta-analysis. JAMA 2012,
308(10):1024–1033.
11. Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B: Omega 3 fatty acids and
cardiovascular outcomes: systematic review and meta-analysis.
Circ Cardiovasc Qual Outcomes 2010, 5:808–818.
12. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF,
Renaud S: Fish, meat, and risk of dementia: cohort study. BMJ 2002,
325:932–933.
13. Lakhan SE, Vieira KF: Nutritional therapies for mental disorders.
Nutr J 2008, 7:2.
14. Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L: Cognitive
and physiological effects of omega-3 polyunsaturated fatty acid
supplementation in healthy subjects. Eur J Clin Invest 2005, 35:691–699.
15. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y,
Sakakibara M, Yoshimoto T, Guo J, Yamashima T: Dietary supplementation
of arachidonic and docosahexaenoic acids improves cognitive
dysfunction. Neurosci Res 2006, 56:159–164.
16. Solfrizzi V, Capurso C, D’Introno A, Colacicco AM, Frisardi V, Santamato A,
Ranieri M, Fiore P, Vendemiale G, Seripa D, Pilotto A, Capurso A, Panza F:
Dietary fatty acids, age-related cognitive decline, and mild cognitive
impairment. J Nutr Health Aging 2008, 12(6):382–386.
17. Feart C, Peuchant E, Letenneur L, Samieri C, Montagnier D, Fourrier-Reglat
A, Barberger-Gateau P: Plasma eicosapentaenoic acid is inversely
associated with severity of depressive symptomatology in the elderly:
data from the Bordeaux sample of the three-City study. Am J Clin Nutr
2008, 87:1156–1162.18. Ruxton CHS, Calder PC, Reed SC, Simpson MJA: The impact of long-chain
n-3 polyunsaturated fatty acids on human health. Nutr Res Rev 2005,
18:113–129.
19. Ooyen C, Link C, Johnson J, Lynch E, Brush M, Rea P (Eds): Nutrition Business
Journal’s 2012 Supplement Business Report. Boulder, CO: Penton Media Inc; 2012.
20. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM,
Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer
MA, Taubert KA: AHA/ACC guidelines for secondary prevention for
patients with coronary and other atherosclerotic vascular disease: 2006
update. J Am Coll Cardiol 2006, 47:2130–2139.
21. Ware JE, Kosinski M, Keller SD: A 12-item short-form health survey:
construction of scales and preliminary tests of reliability and validity.
Med Care 1996, 34(3):220–233.
22. Jenkinson C, Layte R, Jenkinson D, Lawrence K, Petersen S, Paice C, Stradling
J: A shorter form health survey: can the SF-12 replicate results from the
SF-36 in longitudinal studies? J Public Health Med 1997, 19(2):179–186.
23. Lim LL, Fisher JD: Use of the 12-item short-form (SF-12) health survey in
an Australian heart and stroke population. Qual Life Res 1999, 8(1–2):1–8.
24. Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR,
West SG: Dose–response effects of omega-3 fatty acids on triglycerides,
inflammation, and endothelial function in healthy persons with
moderate hypertriglyceridemia. Am J Clin Nutr 2011, 93:243–252.
25. Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS:
Omega-3 augmentation of sertraline in the treatment of depression in
patients with coronary heart disease: a randomized controlled trial.
JAMA 2009, 302(15):1651–1657.
26. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS: n-3
polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal
myocardial infarction in older adults: the cardiovascular health study.
Am J Clin Nutr 2003, 77:319–325.
27. Harris WS, Reid KJ, Sands SA, Spertus JA: Blood omega-3 and trans fatty
acids in middle-aged acute coronary syndrome patients. Am J Cardiol
2007, 99:154–188.
28. Harris WS, von Schacky C: The omega-3 index: a new risk factor for death
from coronary heart disease? Prev Med 2004, 39:212–220.
29. von Schacky C: Use of red blood cell fatty-acid profiles as biomarkers in
cardiac disease. Biomark Med 2009, 3(1):25–32.
30. Block RC, Dier U, Calderon Artero P, Shearer GC, Kakinami L, Larson MK,
Harris WS, Georas S, Mousa SA: The effects of EPA + DHA and aspirin on
inflammatory cytokines and angiogenesis factors. World J Cardiovasc Dis
2012, 2(1):14–19.
31. Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA:
Association of marine omega-3 fatty acid levels with telomeric aging in
patients with coronary heart disease. JAMA 2010, 303(3):250–257.




Cite this article as: Udani and Ritz: High potency fish oil supplement
improves omega-3 fatty acid status in healthy adults: an open-label
study using a web-based, virtual platform. Nutrition Journal 2013 12:112.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
